梅原, 英裕 Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
沼田, 周助 Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
渡部, 真也 Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University KAKEN研究者をさがす
ハタケヤマ, ユタカ Center of Medical Information Science, Kochi Medical School, Kochi University
木下, 誠 Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
富岡, 有紀子 Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University 徳島大学 教育研究者総覧
ナカハラ, キヨシ Research Institute, Kochi University of Technology
二川, 健 Department of Nutritional Physiology, Institute of Medical Nutrition, Tokushima University Graduate School 徳島大学 教育研究者総覧 KAKEN研究者をさがす
Capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS) is a comprehensive, quantitative, and high throughput tool used to analyze metabolite profiles. In the present study, we used CE-TOFMS to profile metabolites found in the blood plasma of 33 medication-free patients with major depressive disorder (MDD) and 33 non-psychiatric control subjects. We then investigated changes which occurred in the metabolite levels during an 8-week treatment period. The medication-free MDD patients and control subjects showed significant differences in their mean levels of 33 metabolites, including kynurenine (KYN), glutamate (Glu), glutamine (Gln), methionine sulfoxide, and methionine (Met). In particular, the ratios of KYN to tryptophan (TRP), Gln to Glu, and Met to methionine sulfoxide were all significantly different between the two groups. Among the 33 metabolites with altered levels in MDD patients, the levels of KYN and Gln, as well as the ratio of Gln to Glu, were significantly normalized after treatment. Our findings suggest that imbalances in specific metabolite levels may be involved in the pathogenesis of MDD, and provide insight into the mechanisms by which antidepressant agents work in MDD patients.
Copyright© The Author(s) 2017 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LID201707104001.pdf 1.12 MB